Clinical grade vector production: Analysis of yield, stability, and storage of GMP-produced retroviral vectors for gene therapy

Biotechnology Progress

Volumn 20, Issue 4, 2004, Pages 1198-1203

  Wikström, Kristina ^a   Blomberg, Pontus ^a   Islam, Khalid B ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; ENERGY STORAGE; STABILITY; YIELD STRESS;

CELLCUBE BIOREACTOR; CLINICAL GRADE VECTOR PRODUCTION; GOOD MANUFACTURING PRACTICE (GMP);

GENE TRANSFER;

PRIMER DNA;

ARTICLE; GENE THERAPY; GENE VECTOR; GENETICS; NUCLEOTIDE SEQUENCE; RETROVIRUS;

BASE SEQUENCE; DNA PRIMERS; GENE THERAPY; GENETIC VECTORS; RETROVIRIDAE;

UNIDENTIFIED RETROVIRUS;

EID: 4043123892     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1021/bp030065g     Document Type: Article

References (13)

1. Thomas, C. E.; Ehrhardt, A.; Kay, M. A. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 2003, 4(5), 346-358.
2. Weber, E.; Anderson, W. F.; Kasahara, N. Recent advances in retrovirus vector-mediated gene therapy: teaching an old vector new tricks. Curr. Opin. Mol. Ther. 2001, 3 (5), 439-453.
3. Andreadis, S. T.; Roth, C. M.; Le Doux, J. M.; Morgan, J. R.; Yarmush, M. L. Large-scale processing of recombinant retroviruses for gene therapy. Biotechnol. Prog. 1999, 15 (1), 1-11.
4. Merten, O. W.; Cruz, P. E.; Rochette, C.; Geny-Fiamma, C.; Bouquet, C.; Goncalves, D.; Danos, O.; Carrondo, M. J. T. Comparison of different bioreactor systems for the production of high titer retroviral vectors. Biotechnol. Prog. 2001, 17 (2), 326-335.
5. Smith, K. T. et al. Gene delivery systems for use in gene therapy: an overview of quality assurance and safety issues. Gene Ther. 1996, 3 (3), 190-200.
6. Eckert, H. G. et al. Clinical scale production of an improved retroviral vector expressing the human multidrug resistance 1 gene (MDR1). Bone Marrow Transplant. 2000, 25 Suppl 2, S114-117.
7. Le Doux, J. H. M. et al. Kinetics of retrovirus production. Biotechnol. Bioeng. 1999, 63 (6), 654-662.
8. Cruz, P. E.; Almeida, J. S.; Murphy, P. N.; Moreira, J. L.; Carrondo, M. J. T. Modeling retrovirus production for gene therapy. 1. Determination Of optimal bioreaction mode and harvest strategy. Biotechnol. Prog. 2000, 16 (2), 213-221.
9. Reeves, L.; Smucker, P.; Cornetta, K. Packaging cell line characteristics and optimizing retroviral vector titer: the National Gene Vector Laboratory experience. Hum. Gene Ther. 2000, 11 (15), 2093-2103.
10. Ng, Y. Y. et al. Frape-1 and Frape-3: two different recombinant retroviruses encoding the same human marker gene. Cancer Gene Ther. 2000, 7 (4), 624-628.
11. Kinsella, T. M.; Nolan, G. P. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum. Gene Ther. 1996, 7 (12), 1405-1413.
12. Lee, S.-G. et al. Optimization of environmental factors for the production and handling of recombinant retroviruses. Appl. Microbiol. Biotechnol. 1996, 45, 477-483.
13. Kaptein, L. C. M.; Greijer, A. E.; van Beuseschem, V. W. Optimized conditions for the production of recombinant amphotropic retroviral vector preparation. Gene Ther. 1997, 4, 172-176.